Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
SOUTH SAN FRANCISCO, Calif. - Twist Bioscience Corporation (NASDAQ: TWST), a leading company in synthetic DNA production using its silicon platform, announced the launch of its Twist Precision Dx next-generation sequencing (NGS) products that comply with the European Union (EU) in vitro diagnostic regulations (IVDR). These products are designed to provide accurate and reliable results for whole exome sequencing, an important tool in genomic research and precision medicine.
The EU has implemented IVDR regulations to ensure the safety, performance, and quality of in vitro diagnostic medical devices, which includes NGS products. Compliance with these regulations is crucial for companies operating in the EU market. Twist Bioscience has proactively developed its Precision Dx products to align with these regulations, demonstrating its commitment to providing high-quality and reliable diagnostic solutions.
Whole exome sequencing involves the analysis of all protein-coding regions, known as exons, in an individual’s genome. This approach allows researchers and clinicians to identify genetic variations that may be responsible for various diseases, including cancer, rare genetic disorders, and hereditary conditions. The availability of IVDR-compliant NGS products is a significant milestone in precision medicine, as it enhances the reliability and regulatory compliance of diagnostic solutions, enabling healthcare providers to make more accurate and informed treatment decisions.
Twist Bioscience’s Precision Dx products are based on its innovative silicon-based DNA synthesis platform, which enables the production of custom DNA sequences with high fidelity and scalability. By leveraging this technology, Twist Bioscience can offer high-quality DNA samples that are essential for accurate and reliable NGS results. The company’s commitment to IVDR compliance ensures that its products meet the necessary standards for clinical use, providing healthcare professionals with confidence in their diagnostic capabilities.
In addition to compliance with IVDR regulations, Twist Bioscience’s Precision Dx products also offer several advantages over conventional NGS solutions. The company’s silicon-based DNA synthesis platform enables the production of longer DNA fragments, resulting in more comprehensive coverage of the exome. This improved coverage increases the detection of genetic variants, enhancing the sensitivity and specificity of diagnostic tests. Furthermore, Twist Bioscience’s products are manufactured in a reliable and scalable manner, ensuring consistent quality and availability for laboratories and healthcare providers.
The launch of IVDR-compliant Precision Dx products by Twist Bioscience represents a significant development in the field of genomic diagnostics. By aligning with EU regulations, Twist Bioscience demonstrates its commitment to providing safe and reliable diagnostic solutions for healthcare professionals and patients. With the increasing adoption of precision medicine approaches, the availability of IVDR-compliant NGS products is essential in ensuring accurate and personalized treatment plans.
Comments